COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.
An Option for Stroke Protection for AFib Patients Undergoing Ablation
Douglas Gibson, M.D.
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation
Be 18 years of age or older
Have undergone a prior catheter ablation procedure for non-valvular atrial fibrillation within 90 days of consent
Be willing and able to return for required follow-up visits and examinations
Patients must not:
Be enrolled in another investigational study
Have had a stroke or transient ischemic attack (TIA) within the past 60 days of consent
Have an active infection
Have had surgical closure of the left atrial appendage
All treatments and physician visits during the study will take place at Anderson Medical Pavilion.
For more information search NCT# 03795298 on the Clinical Trials website at www.clinicaltrials.gov